ABT
ABBOTT LABORATORIES
Healthcare • CIK: 0000001800
Loading...
Market Cap
$233.13B
P/E (TTM)
16.7x
Rev Growth (TTM)
+6.4%
Net Margin (TTM)
31.6%
FCF Yield (TTM)
3.0%
FCF Margin (TTM)
15.8%
Cash Flow Health
Free Cash Flow8/8 positive
TTM$6.9B
Q3 '25
$2.3B+48%
Q2 '25
$1.5B+66%
FCF Margin
TTM15.8%
Q3 '2520.2%+45%
Sector: 5.8%Above Avg
OCF Margin20.8%
OCF/NI0.66x
CapEx Coverage4.1x
FCF Yield3.0%
FCF Growth (2Y)-7%
Cash Conversion Cycle
187 days
DSO: 62+DIO: 125−DPO: 0
Capital Allocation & Returns
Balanced
Total Shareholder YieldTTM
TTM2.2%
Div Yield1.8%
+Buyback (TTM)0.4%
Balancing returns with reinvestment
Dividend & Payout Metrics
Dividend Yield (TTM)1.8%
FCF Payout Ratio59.4%
Free Cash Flow (TTM)$6.9B
Stock Repurchases (TTM)$906.0M
Capital Return / FCF71.6%
Est. Dividends Paid (TTM)$4.1B
Shows how management rewards shareholders
Operational Efficiency & Returns
Return on Invested CapitalTTM
25.8%
Volatile
+1.3% YoY+6.0%
P25MedianP75
75th pctl (med: 0.1%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
30.2%
8Q: 14.2%
Asset Turnover
0.54x
8Q: 0.56x
Leverage (1+D/E)
1.25x
D/E: 0.25x
DuPont: 20.4% ≈ 25.8% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
3.98x
8Q:4.04x
-14.1%
Invested Cap Turn
0.86x
8Q:0.83x
+9.1%
CapEx Intensity
4.3%
8Q:4.1%
CapEx/Depreciation
1.57x
Asset-based ROIC formula
QUARTERLY TRENDS
Last 8 quarters + TTM
| Metric | TTM | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | $43.8B | $11.4B↑2.0% | $11.1B↑7.6% | $10.4B↓5.6% | $11.0B↑3.2% | $10.6B↑2.5% | $10.4B↑4.1% | $10.0B↓2.7% | $10.2B |
Operating Income | $7.7B | $2.1B↑0.2% | $2.1B↑21.2% | $1.7B↓11.4% | $1.9B↑2.8% | $1.9B↑11.4% | $1.7B↑20.4% | $1.4B↓22.1% | $1.8B |
Net Income | $13.9B | $1.6B↓11.1% | $1.8B↑38.5% | $1.3B↓85.8% | $9.2B↑471.9% | $1.6B↑23.1% | $1.3B↑8.3% | $1.2B↓24.4% | $1.6B |
Operating Cash Flow | $9.1B | $2.8B↑36.2% | $2.0B↑44.5% | $1.4B↓50.6% | $2.9B↑6.0% | $2.7B↑38.0% | $2.0B↑91.2% | $1.0B↓66.3% | $3.0B |
Free Cash Flow | $6.9B | $2.3B↑48.3% | $1.5B↑65.6% | $933.0M↓56.6% | $2.1B↓0.0% | $2.1B↑50.6% | $1.4B↑127.6% | $627.0M↓72.5% | $2.3B |
Total Equity | N/A |
Valuation Analysis
Fair Value
Price-to-EarningsTTM
16.7x
Volatile
8Q: 136.9x+144%
Valuation Lenses
Earnings
16.7x
vs – sector
Cash Flow
37.4x
EV/FCF vs –
Growth-Adj
0.1xPEG
Undervalued for growth
Quality-Adj
0.6P/E per %ROIC
ROIC: 25.8%
Shareholder Returns
Dividend
1.8%
Buyback
0.4%
Total Yield
2.2%
Market Cap$233.13B
EV–
Multi-angle valuation analysis with sector context
Business Quality & Moat
Overall Quality Score
60/100
High Quality
Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)
Returns on Capital
Return on Equity (ROE)Top 25%
28.8%
8Q:–
Return on Invested Capital (ROIC)Top 25%
25.8%
8Q:–
+6.0%
vs Sector:0.1%
DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)
NOPAT Margin: 30.2%
Asset Turnover: 0.54x
Earnings Quality
Cash Conversion
0.66x
OCF / Net Income
FCF Consistency
–
Positive quarters
Competitive Moat Indicators
Pricing Power
Gross Margin55.9%
Capital Efficiency
Invested Capital Turnover0.86x
Working Capital
Cash Conversion Cycle187 days
Growth Quality & Momentum
Moderate Growth
Growth Quality Score
53/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%
Growth Rates
Revenue Growth YoY
6.4%
OpInc Growth YoY
10.7%
EPS Growth YoY
142.2%
FCF 3Y CAGR
-6.8%
Growth Quality Analysis
⚠Working Capital Drag: FCF growth lagging revenue by 13.2%
Margin Quality & Sustainability
Low Quality
Profitability Cascade
Gross
55.9%
Operating
17.6%
Above Avg in sector
Net
31.6%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
—
FCF vs Net Gap
-15.8 pts
FCF: 15.8% | Net: 31.6%
FCF margin lags net margin by 15.8 pts
Quality = stability + cash conversion + low dilution
Balance Sheet & Solvency
Solid
Net Debt / EBITDA
–Net Debt: $5.21B
Interest Coverage
–
Leverage Metrics
Debt-to-Equity
0.25x
Balance sheet risk & solvency analysis